Hans J Salwender

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Mul...

Elotuzumab plus VRd plus ASCT bij myeloom: GMMG-HD6 fase III

Isatuximab plus VRd als inductie bij transplanteerbaar myeloom: GMMG-HD7 fase III